약물유전체학 시장 - 규모, 점유율, 성장률, 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of pharmacogenomics Market

The global pharmacogenomics market is experiencing robust growth, driven by the rapid shift toward personalized medicine and advancements in genomic technologies. The market was valued at USD 3.46 billion in 2025 and is projected to grow to USD 3.79 billion in 2026, reaching USD 8.09 billion by 2034, registering a strong CAGR of 9.95% during the forecast period (2026-2034). North America dominated the market, accounting for a 39.47% share in 2025, supported by advanced healthcare infrastructure, early adoption of precision medicine, and favorable regulatory support.

Pharmacogenomics studies the relationship between a patient's genetic makeup and their response to medications, enabling healthcare providers to optimize drug selection and dosage while minimizing adverse effects. The increasing demand for targeted therapies, rising burden of chronic diseases, and extensive investments in genomic research are significantly fueling market growth.

Market Dynamics

Market Drivers

A major driver of the pharmacogenomics market is the strong emphasis on personalized medicine. Healthcare systems worldwide are increasingly moving away from generalized treatment approaches toward genetically guided therapies that improve efficacy and safety. Advancements in next-generation sequencing (NGS) and bioinformatics have significantly reduced sequencing costs and turnaround times, making pharmacogenomic testing more accessible.

Additionally, the growing geriatric population and increasing prevalence of chronic diseases such as cancer and cardiovascular disorders are accelerating the need for precision-based treatment decisions. Strategic initiatives by key players are further supporting market expansion. For instance, in June 2025, bioMerieux announced the acquisition of Day Zero Diagnostics to strengthen its genome sequencing-based diagnostics portfolio.

Market Restraints

Despite technological progress, the market faces challenges due to the lack of standardization in genetic testing and result interpretation. Variability in testing methodologies and reporting frameworks across laboratories creates inconsistencies, limiting clinicians' confidence in using pharmacogenomic data for treatment decisions. Additionally, the absence of uniform reimbursement policies and regulatory guidelines across regions continues to restrain widespread adoption.

Market Opportunities

The integration of artificial intelligence (AI) with pharmacogenomics presents a significant growth opportunity. AI-driven platforms can analyze large genomic datasets to identify gene-drug interactions, predict treatment outcomes, and optimize dosage regimens. Increasing investments in AI-based precision medicine solutions are expected to unlock new development opportunities.

For example, in December 2024, PGxAI raised USD 1.5 million in funding to enhance its proprietary AI-driven pharmacogenomics algorithms in collaboration with InterSystems.

Market Challenges

A major challenge limiting market scalability is the difficulty in integrating pharmacogenomic data with electronic health record (EHR) systems. Limited interoperability prevents genetic insights from being readily accessible at the point of care. Although initiatives are underway to improve data integration, inconsistent adoption of clinical decision support tools continues to hinder full-scale implementation.

Pharmacogenomics Market Trends

A key trend shaping the market is the increasing incorporation of pharmacogenomic biomarkers in clinical trials and drug development. Regulatory bodies such as the FDA and EMA are encouraging the integration of genetic endpoints in drug labeling and companion diagnostics. This trend is enhancing drug efficacy, reducing trial failures, and accelerating regulatory approvals.

For instance, in August 2024, Illumina received FDA approval for its TruSight Oncology comprehensive test, capable of analyzing over 500 genes, highlighting the growing importance of genomics in oncology-focused pharmacogenomics.

Segmentation Analysis

By type, the services segment dominated the market in 2024 due to rising demand for genetic data interpretation and clinical reporting.

By technique, next-generation sequencing (NGS) held a significant market share owing to its ability to analyze multiple genetic variants simultaneously.

By application, personalized medicine dominated the market, driven by the shift toward tailored therapies.

By disease, oncology accounted for the largest share in 2024 due to the strong genetic basis of cancer and growing demand for targeted cancer therapies.

By end-user, academic and research institutes led the market, supported by extensive genomic research and government-funded studies.

Regional Outlook

North America led the market with a valuation of USD 1.36 billion in 2025 and USD 1.49 billion in 2026, driven by high healthcare expenditure, strong research infrastructure, and regulatory support.

Europe held a significant share due to collaborative genomic initiatives and favorable healthcare policies.

Asia Pacific is expected to register the highest CAGR during the forecast period, supported by rising healthcare investments and national genomics programs in countries such as China, Japan, and India.

Competitive Landscape

The market is moderately consolidated, with key players such as Illumina, Thermo Fisher Scientific, Qiagen, and F. Hoffmann-La Roche Ltd. holding substantial market share. These companies are focusing on strategic collaborations, technology sharing, and portfolio expansion to strengthen their market presence.

Conclusion

The global pharmacogenomics market is set for significant expansion, driven by the accelerating adoption of personalized medicine, advancements in sequencing technologies, and growing integration of genomics into clinical decision-making. While challenges related to standardization, data integration, and reimbursement persist, emerging opportunities in AI-enabled pharmacogenomics and expanding applications in oncology and chronic disease management are expected to sustain market growth. With strong investments in research, supportive regulatory initiatives, and increasing clinical adoption, the pharmacogenomics market is poised to witness robust growth through 2034, reinforcing its critical role in the future of precision healthcare.

Segmentation By Type

• Products
  • Consumables
  • Equipment
• Services

By Technique

• Next Generation Sequencing
• Polymerase Chain Reaction
• Microarrays
• In-situ Hybridization
• Others

By Application

• Personalized Medicine
• Drug Discovery
• Others

By Disease

• Oncology
• Neurology
• Cardiology
• Others

By End-user

• Academic and Research Institutes
• Pharmaceutical and Biotechnology Companies
• Others

By Region

• North America (By Type, Technique, Application, Disease, End-user, and Country)
  • U.S.
  • Canada
• Europe (By Type, Technique, Application, Disease, End-user, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• Asia Pacific (By Type, Technique, Application, Disease, End-user, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America (By Type, Technique, Application, Disease, End-user, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, Technique, Application, Disease, End-user, and Country/Sub-region)
  • GCC
  • South Africa
  • Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. New Product Launches, By Key Players
• 4.2. Key Industry Developments (Mergers, Acquisitions, Partnerships, and Others)
• 4.3. Technological Advancements

5. Global Pharmacogenomics Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Products
    • 5.1.1.1. Consumables
    • 5.1.1.2. Equipment
  • 5.1.2. Services
• 5.2. Market Analysis, Insights and Forecast - By Technique
  • 5.2.1. Next Generation Sequencing
  • 5.2.2. Polymerase Chain Reaction
  • 5.2.3. Microarrays
  • 5.2.4. In-situ Hybridization
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By Application
  • 5.3.1. Personalized Medicine
  • 5.3.2. Drug Discovery
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Disease
  • 5.4.1. Oncology
  • 5.4.2. Neurology
  • 5.4.3. Cardiology
  • 5.4.4. Others
• 5.5. Market Analysis, Insights and Forecast - By End-user
  • 5.5.1. Academic and Research Institutes
  • 5.5.2. Pharmaceutical and Biotechnology Companies
  • 5.5.3. Others
• 5.6. Market Analysis, Insights and Forecast - By Region
  • 5.6.1. North America
  • 5.6.2. Europe
  • 5.6.3. Asia Pacific
  • 5.6.4. Latin America
  • 5.6.5. Middle East & Africa

6. North America Pharmacogenomics Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Products
    • 6.1.1.1. Consumables
    • 6.1.1.2. Equipment
  • 6.1.2. Services
• 6.2. Market Analysis, Insights and Forecast - By Technique
  • 6.2.1. Next Generation Sequencing
  • 6.2.2. Polymerase Chain Reaction
  • 6.2.3. Microarrays
  • 6.2.4. In-situ Hybridization
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By Application
  • 6.3.1. Personalized Medicine
  • 6.3.2. Drug Discovery
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Disease
  • 6.4.1. Oncology
  • 6.4.2. Neurology
  • 6.4.3. Cardiology
  • 6.4.4. Others
• 6.5. Market Analysis, Insights and Forecast - By End-user
  • 6.5.1. Academic and Research Institutes
  • 6.5.2. Pharmaceutical and Biotechnology Companies
  • 6.5.3. Others
• 6.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 6.6.1. U.K.
  • 6.6.2. Germany
  • 6.6.3. France
  • 6.6.4. Spain
  • 6.6.5. Italy
  • 6.6.6. Scandinavia
  • 6.6.7. Rest of Europe

7. Asia Pacific Pharmacogenomics Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Products
    • 7.1.1.1. Consumables
    • 7.1.1.2. Equipment
  • 7.1.2. Services
• 7.2. Market Analysis, Insights and Forecast - By Technique
  • 7.2.1. Next Generation Sequencing
  • 7.2.2. Polymerase Chain Reaction
  • 7.2.3. Microarrays
  • 7.2.4. In-situ Hybridization
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By Application
  • 7.3.1. Personalized Medicine
  • 7.3.2. Drug Discovery
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Disease
  • 7.4.1. Oncology
  • 7.4.2. Neurology
  • 7.4.3. Cardiology
  • 7.4.4. Others
• 7.5. Market Analysis, Insights and Forecast - By End-user
  • 7.5.1. Academic and Research Institutes
  • 7.5.2. Pharmaceutical and Biotechnology Companies
  • 7.5.3. Others
• 7.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 7.6.1. Japan
  • 7.6.2. China
  • 7.6.3. India
  • 7.6.4. Australia
  • 7.6.5. Southeast Asia
  • 7.6.6. Rest of Asia Pacific

8. Latin America Pharmacogenomics Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Products
    • 8.1.1.1. Consumables
    • 8.1.1.2. Equipment
  • 8.1.2. Services
• 8.2. Market Analysis, Insights and Forecast - By Technique
  • 8.2.1. Next Generation Sequencing
  • 8.2.2. Polymerase Chain Reaction
  • 8.2.3. Microarrays
  • 8.2.4. In-situ Hybridization
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By Application
  • 8.3.1. Personalized Medicine
  • 8.3.2. Drug Discovery
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Disease
  • 8.4.1. Oncology
  • 8.4.2. Neurology
  • 8.4.3. Cardiology
  • 8.4.4. Others
• 8.5. Market Analysis, Insights and Forecast - By End-user
  • 8.5.1. Academic and Research Institutes
  • 8.5.2. Pharmaceutical and Biotechnology Companies
  • 8.5.3. Others
• 8.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 8.6.1. Brazil
  • 8.6.2. Mexico
  • 8.6.3. Rest of Latin America

9. Middle East & Africa Pharmacogenomics Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Products
    • 9.1.1.1. Consumables
    • 9.1.1.2. Equipment
  • 9.1.2. Services
• 9.2. Market Analysis, Insights and Forecast - By Technique
  • 9.2.1. Next Generation Sequencing
  • 9.2.2. Polymerase Chain Reaction
  • 9.2.3. Microarrays
  • 9.2.4. In-situ Hybridization
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By Application
  • 9.3.1. Personalized Medicine
  • 9.3.2. Drug Discovery
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Disease
  • 9.4.1. Oncology
  • 9.4.2. Neurology
  • 9.4.3. Cardiology
  • 9.4.4. Others
• 9.5. Market Analysis, Insights and Forecast - By End-user
  • 9.5.1. Academic and Research Institutes
  • 9.5.2. Pharmaceutical and Biotechnology Companies
  • 9.5.3. Others
• 9.6. Market Analysis, Insights and Forecast - By Country/Sub-region
  • 9.6.1. GCC
  • 9.6.2. South Africa
  • 9.6.3. Rest of Middle East & Africa

10. Competitive Analysis

• 10.1. Global Market Share Analysis (2025)
• 10.2. Company Profiles
  • 10.2.1. Hoffmann-La Roche Ltd.
    • 10.2.1.1. Overview
    • 10.2.1.2. Products
    • 10.2.1.3. SWOT Analysis
    • 10.2.1.4. Recent Developments
    • 10.2.1.5. Strategies
    • 10.2.1.6. Financials (Based on Availability)
  • 10.2.2. Illumina
    • 10.2.2.1. Overview
    • 10.2.2.2. Products
    • 10.2.2.3. SWOT Analysis
    • 10.2.2.4. Recent Developments
    • 10.2.2.5. Strategies
    • 10.2.2.6. Financials (Based on Availability)
  • 10.2.3. Thermo Fisher Scientific
    • 10.2.3.1. Overview
    • 10.2.3.2. Products
    • 10.2.3.3. SWOT Analysis
    • 10.2.3.4. Recent Developments
    • 10.2.3.5. Strategies
    • 10.2.3.6. Financials (Based on Availability)
  • 10.2.4. Qiagen
    • 10.2.4.1. Overview
    • 10.2.4.2. Products
    • 10.2.4.3. SWOT Analysis
    • 10.2.4.4. Recent Developments
    • 10.2.4.5. Strategies
    • 10.2.4.6. Financials (Based on Availability)
  • 10.2.5. Agilent Technologies
    • 10.2.5.1. Overview
    • 10.2.5.2. Products
    • 10.2.5.3. SWOT Analysis
    • 10.2.5.4. Recent Developments
    • 10.2.5.5. Strategies
    • 10.2.5.6. Financials (Based on Availability)
  • 10.2.6. Myriad Genetics
    • 10.2.6.1. Overview
    • 10.2.6.2. Products
    • 10.2.6.3. SWOT Analysis
    • 10.2.6.4. Recent Developments
    • 10.2.6.5. Strategies
    • 10.2.6.6. Financials (Based on Availability)
  • 10.2.7. Admera Health, LLC
    • 10.2.7.1. Overview
    • 10.2.7.2. Products
    • 10.2.7.3. SWOT Analysis
    • 10.2.7.4. Recent Developments
    • 10.2.7.5. Strategies
    • 10.2.7.6. Financials (Based on Availability)
  • 10.2.8. Bio-Rad Laboratories Inc.
    • 10.2.8.1. Overview
    • 10.2.8.2. Products
    • 10.2.8.3. SWOT Analysis
    • 10.2.8.4. Recent Developments
    • 10.2.8.5. Strategies
    • 10.2.8.6. Financials (Based on Availability)
  • 10.2.9. Eurofins Scientific
    • 10.2.9.1. Overview
    • 10.2.9.2. Products
    • 10.2.9.3. SWOT Analysis
    • 10.2.9.4. Recent Developments
    • 10.2.9.5. Strategies
    • 10.2.9.6. Financials (Based on Availability)
  • 10.2.10. Pathway Genomics
    • 10.2.10.1. Overview
    • 10.2.10.2. Products
    • 10.2.10.3. SWOT Analysis
    • 10.2.10.4. Recent Developments
    • 10.2.10.5. Strategies
    • 10.2.10.6. Financials (Based on Availability)
  • 10.2.11. Other Prominent Players
    • 10.2.11.1. Overview
    • 10.2.11.2. Products
    • 10.2.11.3. SWOT Analysis
    • 10.2.11.4. Recent Developments
    • 10.2.11.5. Strategies
    • 10.2.11.6. Financials (Based on Availability)